CD274 and neoplasm: Next generation sequencing of his metastatic liver tumor demonstrated a high tumor mutational burden (103 mutations per megabase) and the genomic amplification of <i>PD-L1</i>, both of which are features that predict response to anti-PD1/PD-L1 immunotherapy.